Available Dosages
| SKU: | 190 |
|---|---|
| Generic For: | Coreg |
| Active Ingredient: | Carvedilol |
| Manufacturer: | Sun Pharma, India |
Buy Cardivas 3.125mg (Carvedilol) Online
Cardivas 3.125mg is a prescription heart & blood pressure medication containing Carvedilol 3.125mg. The initiation dose of this combined non-selective alpha-1/beta-adrenergic receptor blocker is used as the starting point for Carvedilol therapy in patients with chronic heart failure with reduced ejection fraction (HFrEF), hypertension, and stable angina. Cardivas 3.125mg is the essential first dose at which Carvedilol treatment must always be started — regardless of indication — to allow haemodynamic adaptation to the drug’s combined alpha and beta blockade before the dose is titrated upward through 6.25mg, 12.5mg, and 25mg twice daily to the target maintenance dose. Carvedilol’s combined vasodilation and heart rate reduction can produce symptomatic hypotension in susceptible patients, particularly in patients with heart failure and already compromised cardiac output; the 3.125mg starting dose minimises this risk, allowing the heart and peripheral vasculature to adjust to Carvedilol’s dual pharmacological action before advancing to clinically effective doses.
What is Cardivas 3.125mg?
Cardivas 3.125mg is an oral tablet containing Carvedilol 3.125mg — the lowest approved dose in the Carvedilol range and the dose specifically designated for treatment initiation in heart failure, hypertension, and post-MI left ventricular dysfunction. Initiating Carvedilol at this low dose reflects the unique cardiovascular pharmacology of this drug. Because Carvedilol simultaneously reduces cardiac output (beta-blockade) and peripheral vascular resistance (alpha-1 blockade), initiating it at standard doses in a patient with already compromised haemodynamics can cause acute hypotension and worsening heart failure symptoms. Starting at 3.125mg twice daily allows the prescribing physician to verify tolerability — confirming that heart failure is not acutely decompensating and that blood pressure is maintained — before advancing through the titration schedule that leads to the target 25mg twice-daily maintenance dose associated with the mortality reduction benefit of the pivotal clinical trials.
Manufacturer: Cardivas 3.125mg is manufactured by Sun Pharma, a leading global pharmaceutical company with a broad cardiovascular portfolio and manufacturing facilities certified to international quality standards. The Cardivas brand’s availability across all four dose strengths (3.125mg, 6.25mg, 12.5mg, and 25mg) from a single manufacturer ensures consistent tablet quality throughout the titration journey.
The active component and mode of action of Cardivas 3.125mg
Cardivas 3.125mg contains Carvedilol as its active ingredient, a beta-blocker with additional alpha-blocking properties. It works by blocking beta-1, beta-2, and alpha-1 adrenergic receptors in the body. This action slows the heart rate, reduces the force of heart contractions, and relaxes blood vessels, thereby lowering blood pressure and improving blood flow. By decreasing the workload on the heart, Cardivas helps manage conditions such as high blood pressure, heart failure, and certain heart-related disorders. Its combined effects help improve heart function, reduce strain on the cardiovascular system, and lower the risk of complications.
Clinical Uses of Carvedilol 3.125mg
Cardivas 3.125mg is the mandatory starting dose for all patients initiating Carvedilol therapy for any indication. For chronic heart failure with reduced ejection fraction — the primary evidence-based indication — all major heart failure guidelines (ESC, ACC/AHA, HFA) specify that Carvedilol must be initiated at 3.125mg twice daily in stable, non-decompensated patients and titrated upward at a minimum of 2-week intervals as tolerated. The 3.125mg dose may also be maintained as the long-term dose in patients with HFrEF who cannot tolerate higher doses due to persistent symptomatic hypotension, significant bradycardia, or other haemodynamic constraints; even at this low dose, some neurohormonal benefit is expected from Carvedilol therapy. For hypertension in patients who are particularly sensitive to beta-blocker initiation — elderly patients, those with bradycardia, or those with very labile blood pressure — 3.125mg twice daily provides a cautious entry point before advancing to the 6.25 to 12.5mg range used for adequate antihypertensive control.
Comparing Cardivas 3.125mg and Coreg 3.125mg: Brand vs Generic Differences
Coreg 3.125mg (GSK) is the originator-branded Carvedilol product at the initiation dose — the formulation used in all the landmark heart failure trials, where the titration protocol beginning at 3.125mg twice daily is specified as the treatment protocol. Cardivas 3.125mg contains Carvedilol 3.125mg, formulated to deliver bioequivalent plasma Carvedilol exposure to the reference product, confirming equivalent alpha-1 and beta-receptor blockade at the initiation dose and supporting the same safe titration protocol. The clinical evidence from Coreg trials — the COPERNICUS, US Carvedilol, CAPRICORN, and COMET outcomes studies — is directly applicable to Cardivas, a bioequivalent generic Carvedilol product, across the full dose range.
Related strengths and products: After completing 2 weeks at 3.125mg twice daily without adverse events, patients advance to Cardivas 6.25mg as the next titration step, continuing through Cardivas 12.5mg to Cardivas 25mg — the target maintenance dose. Complementary heart failure pharmacotherapy available at AllDayChemist includes Amlopres 5mg (Amlodipine) for additional vasodilation in select heart failure patients.
Key Benefits of Cardivas 3.125mg
Cardivas 3.125mg provides the critical first dose of the Carvedilol titration protocol that, if completed successfully to the target 25mg twice-daily dose, delivers one of the most evidence-backed reductions in mortality in the pharmacotherapy of heart failure. By starting at the lowest possible pharmacologically active dose, Cardivas 3.125mg allows the physician to verify haemodynamic tolerability, identify patients in whom heart failure is too unstable for beta-blocker introduction (who require stabilisation first), and give the cardiovascular system the initial adaptation window needed for successful long-term beta-blockade in this fragile patient population. The 15-tablet pack provides a 7.5-day supply at twice-daily dosing — covering the initial 2-week evaluation period with a small buffer — appropriate for the closely monitored early phase of Carvedilol initiation.
Usage warnings and precautionary advice for using Carvedilol 3.125mg
Cardivas 3.125mg must never be initiated in patients with acute decompensated heart failure, significant fluid overload, or haemodynamic instability — heart failure must be clinically stable and optimised on diuretics and ACE inhibitors or ARBs before Carvedilol is started. Carvedilol is absolutely contraindicated in patients with significant bronchospasm; the beta-2 blockade component precludes its use in asthma and severe COPD with reversible airway obstruction. Concurrent calcium channel blockers of the non-dihydropyridine class (verapamil, diltiazem) should not be used with Carvedilol due to the risk of severe bradycardia and AV block; separate the use of these drug classes. In patients taking insulin or oral antidiabetic agents, Carvedilol’s non-selective beta-blockade can prolong or mask the haemodynamic signs of hypoglycaemia; increased glucose monitoring is required.
Side effects of Carvedilol 3.125mg
At the 3.125mg initiation dose, Carvedilol’s adverse effects are significantly attenuated compared to higher doses. Still, the clinical importance of those that do occur is magnified in the vulnerable heart failure population. Dizziness and symptomatic orthostatic hypotension are the most common initiation side effects and are most likely in the first few days of treatment; taking with food reduces this risk. Fatigue and tiredness are commonly reported and reflect reduced cardiac output from beta-blockade. Fluid retention and weight gain — indicating worsening heart failure — can occur in the first 2 to 4 weeks of Carvedilol initiation as the heart adapts; these usually resolve with diuretic dose adjustment rather than Carvedilol discontinuation. Bradycardia is expected and should prompt heart rate monitoring; a rate below 50 bpm requires dose review. Peripheral coldness from reduced peripheral blood flow occurs in some patients.
Benefits of Buying Cardivas 3.125mg Online from AllDayChemist
AllDayChemist provides Cardivas 3.125mg at accessible prices with reliable international home delivery — including both the initiation dose and all subsequent titration strengths — ensuring that patients beginning Carvedilol therapy can source each step of the titration protocol from a single, dependable platform. The availability of all four Cardivas dose strengths at AllDayChemist supports seamless titration management from initiation through to the target dose.
Proper dosage and usage guide of Carvedilol 3.125mg
Take one Cardivas 3.125mg tablet twice daily, with food. Food reduces the risk of orthostatic hypotension and improves tolerability. Heart failure initiation: 3.125mg twice daily for 2 weeks; if tolerated without significant hypotension (systolic BP below 90 mmHg) or symptomatic bradycardia, advance to 6.25mg twice daily and continue the 2-weekly titration schedule under physician supervision. Blood pressure and heart rate must be checked before each dose increase. Do not stop Carvedilol abruptly — even at this low dose, sudden discontinuation can cause rebound sympathetic activation and clinical deterioration in patients with heart failure; if treatment needs to be stopped, taper slowly over 1 to 2 weeks. If the patient experiences acute decompensation during titration, return to the previously tolerated dose rather than completely stopping. Store at room temperature below 30°C, in a dry place away from moisture.
What is Cardivas 3.125mg used for?
Cardivas 3.125mg contains Carvedilol 3.125mg, a non-selective beta blocker with additional alpha-1 blocking activity. It is used to treat heart failure (as an adjunct to standard therapy), hypertension, and stable angina. In heart failure, Carvedilol is one of only three beta blockers proven to reduce mortality, making Cardivas 3.125mg a critical starting dose in that indication.
How does Carvedilol in Cardivas 3.125mg work?
Carvedilol in Cardivas 3.125mg helps the heart work more efficiently by blocking certain stress-related signals that can increase heart rate and blood pressure. It relaxes blood vessels and slows the heartbeat, reducing the strain on the heart. This action helps improve blood flow and lowers the risk of complications linked with heart failure, high blood pressure, and certain heart conditions. By decreasing the heart’s workload, Cardivas 3.125mg may also help reduce symptoms such as tiredness, shortness of breath, and chest discomfort when taken regularly.
Why is Cardivas 3.125mg such a low dose?
Cardivas 3.125mg is the mandated starting dose for heart failure according to major cardiology guidelines. In heart failure, the heart is in a compensated but fragile state, and starting at higher doses of beta blockers can cause acute decompensation. The 3.125mg dose is doubled at two-week intervals (3.125mg → 6.25mg → 12.5mg → 25mg) as tolerated, a process called up-titration, to reach the target maintenance dose.
How should Cardivas 3.125mg be taken?
Cardivas 3.125mg should be taken twice daily with food. Meals slow absorption and reduce the risk of postural hypotension. Take it at the same times each day — for example, with breakfast and dinner. Do not take on an empty stomach. If you miss a dose, take it as soon as you remember; if close to the next dose time, skip the missed dose and resume the regular schedule.
Is Cardivas 3.125mg safe for patients with asthma?
No. Carvedilol is a non-selective beta blocker and can cause bronchospasm in patients with asthma or reactive airway disease. It is contraindicated in patients with bronchial asthma or severe chronic obstructive pulmonary disease with a significant bronchospastic component. If you have asthma or COPD, discuss safer alternatives such as a selective beta-1 blocker (e.g., metoprolol or bisoprolol) with your cardiologist.
Can Cardivas 3.125mg be used in diabetic heart failure patients?
Carvedilol has been shown to be safer than non-selective beta blockers in diabetics. Unlike atenolol or propranolol, Carvedilol does not worsen insulin resistance and may even improve glycaemic control slightly through its alpha-blocking component. However, it can mask hypoglycaemia warning signs (tachycardia) — diabetic patients should monitor glucose more closely after starting Cardivas 3.125mg.
How does Cardivas 3.125mg compare to Coreg 3.125mg?
Cardivas 3.125mg and Coreg 3.125mg both contain Carvedilol 3.125mg. Coreg is the originator US brand at a significant premium. Cardivas, manufactured by Sun Pharma in India, is the generic equivalent with identical pharmacological profile. Patients in the USA who switch from Coreg to Cardivas (via AllDayChemist) experience the same cardiac benefit at substantially reduced cost.
Is Carvedilol 3.125mg generically equivalent to Coreg?
Yes. Cardivas 3.125mg is a generic equivalent to Coreg 3.125mg. Regulatory approval requires bioequivalence demonstration — meaning the generic delivers the same systemic exposure as the brand. For a drug like Carvedilol with a proven mortality benefit in heart failure trials, using the generic does not change the clinical outcome. Generic Carvedilol use is widespread in clinical practice globally.
Where can I buy Cardivas 3.125mg at an affordable price?
AllDayChemist offers Cardivas 3.125mg with international shipping to the USA, UK, Australia, and 200+ countries. Licensed since 2002, AllDayChemist provides authentic medicines sourced directly from the manufacturer (Sun Pharma). Orders ship in discreet, plain packaging with tracking. Free shipping is available on qualifying orders.
Why is AllDayChemist a preferred source for cardiac medications like Cardivas?
AllDayChemist has operated since 2002, building a reputation for genuine, manufacturer-sourced cardiac medications across 200+ countries. Cardivas 3.125mg is priced significantly lower than US or UK retail, making the essential heart failure up-titration process financially accessible. Discreet packaging, free international shipping, and knowledgeable customer support make AllDayChemist a comprehensive solution.
What side effects are associated with Cardivas 3.125mg?
Common side effects of Carvedilol 3.125mg include dizziness, fatigue, hypotension (especially on standing), bradycardia (slow heart rate), and weight gain due to fluid retention. Dizziness is more common when starting or up-titrating the dose. Hypoglycaemia warning signs may be masked in diabetics. Worsening heart failure symptoms during the initiation phase should be reported to your cardiologist promptly.
What precautions should I take with Cardivas 3.125mg?
Never stop Cardivas 3.125mg abruptly — sudden withdrawal can trigger rebound hypertension or angina deterioration. Take with food to reduce postural hypotension. Report any worsening breathlessness, significant weight gain (more than 2kg in two days), or ankle swelling, which may signal fluid decompensation. Inform your surgeon before any operation as beta blockers interact with anaesthetic agents. Do not use over-the-counter cold remedies containing sympathomimetics.
Leading Online Pharmacy
100% Genuine
Products
& OTC Products
Login
Sign up
Leading Online Pharmacy
100% Genuine
Products
& OTC Products
Login
Sign Up
Leading Online Pharmacy
100% Genuine
Products
& OTC Products
Forgot Password ?